Insight
Beyond Clinic
Insight

Information about skin treatments, common questions, and care decisions.

Research Reviews

RF Microneedling in Aged Skin: Findings, Limits, and Why This Was Not a Potenza Trial

Written by Beyond Clinic editorial team · Medically reviewed by Hyojung Moon, MD · Published

A randomized split-face trial enrolled 30 Korean women aged 60 or older and compared microneedle radiofrequency (MNRF) with microneedling without RF around the eyes. Some wrinkle, elasticity, and hydration measures changed significantly from baseline at 5 months. Tissue analysis found fewer senescent fibroblasts, skin cells that have permanently stopped dividing, and greater collagen density in the papillary dermis, the upper dermal layer, on the MNRF side than on the microneedling side. Potenza is a Jeisys Medical MNRF platform; this trial used another manufacturer’s device. The small sample, lack of direct tests comparing clinical change between groups, changes on the microneedling side, and absence of pretreatment biopsies limit interpretation. Long-term safety and rare complications were not established, and these findings cannot be transferred to other devices or areas.

  • Some wrinkle, elasticity, and hydration measures changed significantly on the MNRF side, but direct statistical tests of superiority in clinical change between the groups were not provided.
  • Tissue findings favored the MNRF side for senescent fibroblast counts and papillary dermal collagen density. Differences in the reticular dermis, the deeper dermal layer, were not statistically significant, and no pretreatment biopsies established tissue changes from baseline.
  • Thirty women aged 60 or older were enrolled. Final assessment was 8 weeks, about 2 months, after the last session, limiting conclusions about persistence, long-term safety, rare complications, and other populations or areas.

At the 5-month assessment, some wrinkle and elasticity measures, hydration, and transepidermal water loss (TEWL), the passage of water through skin, differed significantly from baseline on the MNRF side. Tissue samples showed fewer p16INK4A-positive senescent fibroblasts, more non-senescent fibroblasts, and higher collagen density and elastin fluorescence in the papillary dermis, the shallow dermal layer, than on the microneedling side. Clinical data came from 29 participants and tissue analyses from 25–26. Several measures were nonsignificant, and the microneedling side also changed in some wrinkle measures. These findings belong to the studied device and conditions.[1,2]

The commercial examples below illustrate how energy reaches tissue. They are not the trial’s effect or safety results, Beyond Clinic treatment outcomes, or forecasts for an individual. Individual suitability and safety require medical assessment.

Hwang and colleagues conducted a prospective, double-blind, randomized split-face trial at Seoul National University Hospital. It was published in Scientific Reports in 2025. Participants received four sessions at 4-week intervals and final assessment 8 weeks after the last session. The study had institutional ethics approval. Viol supplied research funding and the device; the authors stated that the company did not participate in design, data collection, analysis, or manuscript preparation.[1]

Key findings

  • Device distinction: The trial used another manufacturer’s MNRF platform. The commercial examples below explain mechanisms and cannot serve as the subjects of this study’s effect or safety claims.
  • Biophysical findings: Some wrinkle and elasticity measures, hydration, and TEWL changed significantly from baseline at 5 months on the MNRF side. Wrinkle R4; elasticity R0, R3, R6, R8, and R9; and melanin and erythema indices did not. Some wrinkle measures also changed on the microneedling side. Direct tests comparing the amounts of clinical change were not supplied.
  • Tissue findings: The MNRF side had fewer p16INK4A-positive senescent fibroblasts, more non-senescent and procollagen-1-positive cells, and greater papillary dermal collagen density and elastin fluorescence. Reticular dermal differences were nonsignificant. Raw graph means and individual exact p values were not tabulated, and no pretreatment biopsy was taken.
  • Exploratory subgroup: Twelve responders with larger differences in senescent fibroblasts between sides also showed collagen-density and hydration differences. This small subgroup was defined after the results were available; it cannot establish causation or predict an individual’s response.
  • Adverse events: Redness (erythema), swelling (edema), bruising, itching (pruritus), and tingling showed no significant between-side differences (p = 0.056–0.754). Reported events were mild and lasted 10 minutes to 7 days. These observations were limited to 29 participants’ periorbital skin, four sessions, and 2 months after the final session.
  • Study scope: Giving both conditions to the same person’s opposite sides can reduce some individual variation. The small sample had no reported advance power calculation; all participants were Korean women, with a mean age of 65.8 years. The findings do not establish results in other ages, sexes, or areas.[1,2]

Why the study conditions matter

The trial examined some skin measurements and tissue markers under one MNRF protocol. Its findings need to be read with the small sample, nonsignificant measures, changes on the microneedling side, and short follow-up. A device class and an individual commercial platform are different levels of description.

Each participant received RF through needles at 1 mm depth on one periorbital side. The other side received needling at the same depth with RF energy set to 0. That comparison examines mechanical microneedle injury with and without RF heat. It does not compare the commercial examples, noninvasive RF, or focused ultrasound, so tissue findings cannot establish a device ranking.[1]

What the trial examined

Design and participants

Thirty women aged 60 or older with visible fine periorbital wrinkles were enrolled. Computer-generated random allocation determined which side received MNRF and which received microneedling (MN) without RF; participants and evaluators were blinded. Four sessions were given at 4-week intervals. Measurements were taken at baseline, 3 months, and 5 months. Twenty-nine completed clinical follow-up. Tissue was obtained 2 months after the final session; depending on the analysis, samples were available for 25 or 26 people. This is a small study of older Korean women’s periorbital skin.[1]

Biophysical measurements at 5 months

The figures below compare the MNRF side with its baseline and are reported as mean ± standard deviation. The paper does not provide detailed calculation formulas for the R measures; they should not be relabeled arbitrarily as wrinkle depth or a general amount of elasticity.[2]

  • Wrinkles: Visioscan changed from 99.01 ± 8.30 to 91.11 ± 11.40 (p < 0.0001). Visiometer R1 changed from 1.45 ± 0.23 to 1.19 ± 0.14 (p = 0.042); R2, from 1.07 ± 0.25 to 0.85 ± 0.16 (p = 0.0001); R3, from 0.64 ± 0.13 to 0.55 ± 0.09 (p = 0.021); and R5, from 0.22 ± 0.05 to 0.18 ± 0.03 (p = 0.005).
  • Elasticity: R1 changed from 0.11 ± 0.03 to 0.09 ± 0.03 (p = 0.005); R2, from 0.56 ± 0.07 to 0.62 ± 0.07 (p = 0.0001); R4, from 0.15 ± 0.04 to 0.12 ± 0.04 (p = 0.007); R5, from 0.45 ± 0.14 to 0.52 ± 0.13 (p = 0.005); and R7, from 0.27 ± 0.05 to 0.30 ± 0.05 (p = 0.002).
  • Hydration and TEWL: Hydration changed from 59.61 ± 8.05 to 64.27 ± 9.10 (p = 0.016); TEWL changed from 11.35 ± 2.86 to 10.03 ± 2.10 (p = 0.046).[2]

Nonsignificant measures need equal attention. Wrinkle R4 changed from 0.45 ± 0.06 to 0.43 ± 0.08 (p = 0.743). Elasticity R0 (p = 0.125), R3 (p = 0.112), R6 (p = 1.000), R8 (p = 0.459), and R9 (p = 1.000), melanin index (p = 0.327), and erythema index (p = 0.538) also showed no significant difference from baseline at 5 months.[2]

The MN side also changed significantly at 5 months: Visioscan from 98.76 ± 8.26 to 93.35 ± 10.78 (p = 0.015); Visiometer R1 from 1.43 ± 0.29 to 1.23 ± 0.18 (p = 0.0004); R2 from 1.11 ± 0.30 to 0.89 ± 0.18 (p = 0.0004); and R3 from 0.66 ± 0.17 to 0.58 ± 0.10 (p = 0.008). Table 2 p values compare follow-up with baseline within each side. They do not directly test the difference in change between groups, so the table cannot establish clinical superiority.[2]

Tissue findings

At 2 months after the final session, the MNRF side had a lower proportion and absolute number of p16INK4A-positive senescent fibroblasts, and more p16INK4A-negative non-senescent fibroblasts and procollagen-1-positive cells, than the MN side. Papillary dermal collagen density and elastin fluorescence were higher; reticular dermal collagen and elastic-fiber density differences were nonsignificant. These directions come from the dot plots and significance markings in Figures 3–5. Raw group means were not tabulated, so estimating values by eye or inventing individual exact p values would be inappropriate.[1]

The authors defined responders as the upper 50% by the difference in senescent fibroblasts between sides and reanalyzed 12 people. Only this subgroup showed significant collagen-density and hydration differences between sides. Defining a small subgroup from the observed results makes this exploratory: it cannot establish that fewer senescent fibroblasts necessarily cause a particular change or predict a person’s response.[1]

Adverse events and their observation window

Table 3 reported five immediate reactions, with 29 participants in each side’s denominator:[2]

  • Erythema: MN 0 (0%); MNRF 4 (13.79%); p = 0.056.
  • Edema: MN 0 (0%); MNRF 2 (6.90%); p = 0.246.
  • Bruising: MN 1 (3.45%); MNRF 1 (3.45%); p = 0.754.
  • Pruritus, or itching: MN 1 (3.45%); MNRF 1 (3.45%); p = 0.754.
  • Tingling: MN 0 (0%); MNRF 1 (3.45%); p = 0.500.

None showed a statistically significant between-side difference. The authors described the recorded events as mild, lasting 10 minutes to 7 days, and mostly managed with cold compresses. This is the report from 29 participants receiving four sessions around the eyes and observed through 2 months after the final session. It cannot establish rare or long-term risks, or safety with different devices, depths, energy settings, or health conditions.[1,2]

A separate periorbital MNRF study enrolled 11 people, of whom nine completed follow-up. One participant stopped because of pain after the second session, and another did not complete follow-up. The report described a mean numeric pain score of 5.33 and immediate erythema and wheals at needle sites in one participant, resolving within a day. It excluded people who had received collagen, fat, HA, or botulinum toxin injections, chemical peels, lifting surgery, or ablative or nonablative resurfacing laser treatments within the preceding 3 months, as well as those with infectious or inflammatory skin disease, keloid formation, or chronic disease. These are that study’s eligibility limits and adverse-event observations, not universal contraindications or pooled safety data.[8]

MNRF platforms and the conditions actually tested

MNRF combines mechanical needle insertion with RF energy delivered through the electrodes to a chosen tissue depth. Needles pass through the skin surface and epidermis to reach that depth; they do not bypass the epidermis or leave it entirely uninjured. Clinical outcomes still need evidence for the actual device, tip, mode, depth, energy, and session schedule.[1,8]

Platform identity Technical conditions Relationship to the trial
Studied platform: Sylfirm X, Viol Co., Ltd. CW4 continuous mode; 300 ms; 1 mm needle depth; energy levels 3–5, corresponding to 2.42–2.74 J/shot; one pass; four sessions at 4-week intervals. The findings concern this device and fixed protocol together. They do not automatically apply to another setting on the same platform.
Separate Jeisys Medical platform RF delivery through microneedles, with monopolar and bipolar modes in one platform; the technical sources also list 1 MHz and 2 MHz. This was not the trial device. These are specifications, not a link to the trial’s clinical or tissue findings.[3,4]

Sharing the MNRF category does not establish clinical equivalence. The category alone cannot determine effects, safety, or a ranking between platforms.

Different energy paths: needles, surface applicators, and ultrasound

The examples below classify physical delivery paths. The trial directly compared only its MNRF protocol and the same-depth MN condition with RF energy set to 0.

Energy category and example Physical delivery path Interpretation boundary
Microneedle RF, as classified above Needles cross the surface and epidermis, then deliver RF at the selected dermal depth. A delivery path cannot establish superiority in effect or safety.
Noninvasive monopolar RF: Thermage A surface applicator delivers RF without inserted needles; the technical description includes cooling to protect the epidermis. This is a mechanism description, not a result of the MNRF trial.[5]
Noninvasive monopolar RF: XERF A surface applicator delivers multifrequency monopolar RF at 6.78 MHz and 2 MHz without inserted needles. The frequencies do not establish comparative effects or safety.[6]
Focused ultrasound: Ultherapy Microfocused sound energy forms thermal coagulation points at a selected focal depth. This was not an arm of the MNRF trial.[7]

Energy reaches tissue differently through a needle, a surface applicator, or an ultrasound focus. Those differences cannot rank effects, safety, or suitability, and the examples cannot claim the trial’s clinical or tissue findings.

Manufacturer safety information is separate from the trial. The MNRF product page describes redness or swelling for 1–2 days; this is not a recovery forecast for every MNRF device or setting. The focused-ultrasound page lists redness, swelling, pain, and transient nerve effects in clinical trials of that system. These are safety descriptions for the respective systems, not comparative rates or events from this trial.[3,7]

Four ways to interpret the study

1. How tissue markers relate to clinical measurements

The trial paired skin measurements with tissue markers from opposite periorbital sides of the same person. Its findings in some skin measures, senescent fibroblasts, and papillary dermal collagen and elastin suggest a possible connection between clinical observations and tissue findings. They do not confirm a mechanism or establish long-term outcomes.[1]

2. What randomization and blinding can address

Randomization, the split-face design, and blinding reduce some individual variation and assessment bias. The sample remained small: 30 enrolled, 29 clinical completers, and 25–26 tissue samples, with no reported advance power calculation. Some measures were nonsignificant. Without pretreatment tissue, changes in each side’s markers from baseline cannot be measured directly.[1]

3. Which treatment conditions need to match

The protocol used a particular device in CW4 mode at 1 mm depth, with energy levels 3–5 and four sessions. The model, settings, area, intended endpoint, and reactions therefore need consideration together. A class name cannot substitute for evidence in another area, age group, device, or setting.

4. Findings and unanswered questions to discuss

Observed findings belong beside unanswered questions. Some biophysical and tissue findings were significant, but the separate MN side also changed in some measures, direct clinical superiority was not established, and long-term outcomes were not assessed. The actual study conditions matter more than familiarity with a device name.

What to clarify when reading MNRF research

The trial reported some biophysical and tissue findings in older Korean women’s periorbital skin under a specific protocol. Read them with the small sample, short follow-up, nonsignificant measures, MN-side changes, and absent pretreatment biopsies. Clarify the actual model, mode, depth, energy, sessions, evidence for comparable conditions, and expected temporary reactions. Current skin and general health need individual assessment.

Seek medical assessment if redness, swelling, bruising, itching, or tingling lasts longer than expected or worsens after a procedure.

Limits to keep in view

  • Thirty participants enrolled, 29 completed clinical follow-up, and 25–26 contributed to tissue analyses. No advance sample-size or power calculation was reported.
  • All participants were Korean women, with a mean age of 65.8 years, and the study concerned fine periorbital wrinkles. It does not establish results for other ages, sexes, areas, or skin conditions.
  • Final assessment was 8 weeks, about 2 months, after the last session. Persistence, long-term safety, and rare complications remain unanswered.
  • No pretreatment biopsies established tissue changes from baseline; raw group means for tissue graphs were not tabulated.
  • Several biophysical findings were nonsignificant, and some MN wrinkle measures changed significantly. Direct tests comparing the amounts of clinical change between groups were not provided.
  • The 12-person responder analysis was small and conducted after outcomes were available. Viol supplied funding and device support; the statement that the company did not participate in the study is the authors’ declaration.[1]

References

  1. Hwang JM, Lee SH, Baek EJ, et al. “Comparison of the effects of fractional microneedle radiofrequency and microneedling on modulating the senescent fibroblast milieu in aged skin.” Scientific Reports. 2025;15(1):18296. DOI: 10.1038/s41598-025-02545-3. PMID: 40419589. https://www.nature.com/articles/s41598-025-02545-3
  2. Hwang JM, et al. Scientific Reports, Tables 1–3: “Demographic characteristics of the subjects”; “Changes in wrinkles, elasticity, hydration, TEWL, melanin index and erythema index induced by treatment with MN or MNRF”; “Adverse reactions after treatment with MN and MNRF.” https://www.nature.com/articles/s41598-025-02545-3/tables/1 · https://www.nature.com/articles/s41598-025-02545-3/tables/2 · https://www.nature.com/articles/s41598-025-02545-3/tables/3
  3. Jeisys Medical, “POTENZA” (manufacturer product information). https://www.jeisys-us.com/potenza
  4. U.S. Food and Drug Administration, “POTENZA: 510(k) Summary” (technical device record). https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192545.pdf
  5. Thermage, “Technologie & Mode d’action” (in French; manufacturer technical information). https://thermage.fr/technologie-mode-daction/
  6. Cynosure Lutronic, “XERF” (manufacturer product information). https://www.cynosure.com/xerf/
  7. Ultherapy, “Mechanism of Action — Collagen Stimulation” (manufacturer technical information). https://ultherapy.com/physicians/optimized-neocollagenesis
  8. “Periorbital Skin Rejuvenation of Asian Skin Using Microneedle Fractional Radiofrequency.” Annals of Dermatology, Korean Dermatological Association. https://anndermatol.org/DOIx.php?id=10.5021/ad.22.217

Frequently asked questions

Is there research on skin changes with microneedle RF, and is this evidence about Potenza?
A randomized split-face trial enrolled 30 older Korean women, with 29 completing clinical follow-up, and compared microneedle radiofrequency (MNRF) with microneedling without RF around the eyes. Some skin measures and tissue findings differed, but the trial device was Sylfirm X from Viol, not Potenza. Sharing the MNRF category cannot transfer this trial's effect or safety findings to an unstudied platform.

Which changes were statistically significant in the study?
At 5 months, the MNRF side had significant changes from baseline in Visioscan and Visiometer wrinkle R1, R2, R3, and R5; elasticity R1, R2, R4, R5, and R7; hydration; and transepidermal water loss (TEWL). Wrinkle R4, elasticity R0, R3, R6, R8, and R9, and melanin and erythema indices were nonsignificant. The microneedling side also changed significantly in Visioscan and wrinkle R1, R2, and R3. Direct tests comparing the groups' amounts of clinical change were not supplied.

Do fewer senescent fibroblasts mean skin aging was reversed?
That cannot be concluded. At 2 months after the final session, fewer p16INK4A-positive senescent fibroblasts were observed on the MNRF side than on the microneedling side. Without pretreatment biopsies, individual changes from baseline could not be measured directly. Raw graph values were not tabulated, and the 12-person responder analysis was exploratory and conducted after the results were available.

Do Potenza, Thermage, XERF, and Ultherapy use the same method?
They are examples of different energy paths: Potenza is an MNRF platform; Thermage and XERF are noninvasive monopolar RF platforms using surface applicators; Ultherapy is a focused-ultrasound platform forming thermal coagulation points at a focal depth. These classifications do not rank effect or safety.

What should I clarify when discussing this research?
Clarify the exact model and settings, area, number of sessions, and evidence matching those conditions. Ask about expected temporary reactions such as redness, swelling, or bruising and which changes should prompt contact. Share current skin findings and concerns with the clinician. A familiar class or device name cannot answer those questions on its own.

Related reading

Read the Korean original

Questions about your care

Discuss questions about your care with our clinical team.

Once you verify your identity using a passport issued outside Korea, you can book without a Korean phone number. If you have trouble booking, message us on WhatsApp.

Beyond Clinic

Address
6th Floor, JY Building, 826 Nonhyeon-ro, Gangnam-gu, Seoul, South Korea
Contact
+82-2-6408-2080 · +82-2-6408-2081
Business Hours
Mondays and Fridays · 10:00 a.m.–8:00 p.m. · Last appointment at 7:00 p.m.Tuesdays and Thursdays · 10:00 a.m.–7:00 p.m. · Last appointment at 6:00 p.m.Saturdays · 10:00 a.m.–4:00 p.m. · Last appointment at 3:00 p.m.Lunch break: 2:00–3:00 p.m. (no lunch break on Saturdays)Closed Wednesdays, Sundays, and public holidays.